🇺🇸

US SEC Filing Intelligence

· daily

Big Pharma Approvals — June 17, 2026

This digest covers two FDA approvals from June 12, 2026, both classified as 'Other' (non-NME, non-biosimilar, non-label expansion), with a bullish signal mix of 2-0-0. The dominant theme is a mixed-signal day: AbbVie Inc. secured a label expansion for its blockbuster IL-23 inhibitor risankizumab (SKYRIZI), while Bayer HealthCare Pharmaceuticals received an NME approval for an undisclosed Orphan Drug. The highest-conviction signal is Bayer's NME approval, given the 8/10 strength and materiality score and the Orphan Drug designation, which typically confers 7-year market exclusivity and premium pricing potential. The key risk is the lack of disclosed commercial data (peak sales, exclusivity, pricing) for both approvals, limiting full investment thesis validation. Notably, the absence of biosimilar approvals and the single therapeutic area (undisclosed for Bayer) prevent a clear sector clustering signal.

2 total filings
· daily

Orphan Drug Approvals — June 17, 2026

This digest covers two FDA approvals on June 17, 2026, with a mix of zero NMEs, zero biosimilars, zero label expansions, and two 'Other' approvals. The dominant therapeutic area theme is not clearly defined due to one undisclosed drug. The highest-conviction signal is the undisclosed NME from BAYER HEALTHCARE PHARMS, which carries Orphan Drug designation and a strong bullish signal (8/10), suggesting a high-value, niche commercial opportunity. A key risk is the lack of commercial data (peak sales, exclusivity, pricing) for both approvals, limiting precise investment modeling. The ABBVIE INC label expansion for RISANKIZUMAB-RZAA (SKYRIZI) is a lower-conviction bullish signal (5/10), likely reflecting a modest market extension rather than a transformative catalyst.

2 total filings
· daily

Federal Construction & Infrastructure Contracts — June 17, 2026

This digest covers a single $103.3 million civilian infrastructure contract awarded to Kiewit Infrastructure West Co. by the National Park Service for a wastewater treatment plant replacement in Yosemite National Park. The contract is entirely civilian (0% defense-related) and signals stable, long-duration investment in national park infrastructure, with full funding obligated at award providing clear revenue visibility. However, the firm-fixed-price structure transfers significant cost-overrun risk to Kiewit on a complex construction project, and the neutral signal strength (5/10) and low materiality (3/10) suggest limited near-term stock impact. The key risk is execution on a fixed-price, multi-year construction project in a remote, environmentally sensitive location.

1 total filings
· daily

Defense Manufacturing Contracts — June 17, 2026

This digest covers a single $309.6 million defense manufacturing contract, solely within the civilian Department of Transportation (Maritime Administration), not the DoD. TOTE SERVICES, LLC won a competitively awarded, firm-fixed-price delivery order for the NSMV V vessel, with 85% of the value already funded, significantly de-risking future payment exposure. The highest-conviction signal is revenue visibility for TOTE through August 2029, but the fixed-price structure introduces execution risk over the multi-year build. The key watch item is any cost overrun that could compress margins on this single-vessel program.

1 total filings
· daily

HHS & Healthcare Contracts Intelligence — June 17, 2026

The sole contract in this period is a $126.4M cost-plus-fixed-fee delivery order awarded to Leidos Holdings, Inc. by the NIH National Cancer Institute for GOCO R&D facility space management in Frederick, MD. This is a purely civilian, non-defense award, reinforcing Leidos' entrenched position in federal life sciences R&D support. The neutral signal (strength 6/10, materiality 4/10) reflects stable, low-risk revenue but limited upside due to the cost-plus pricing structure and a fixed end date in August 2024. Key risks include NIH budget appropriation uncertainty for FY2024 and the absence of options for extension, which could create a revenue gap for Leidos' health segment.

1 total filings
· daily

New Federal Contractors — June 17, 2026

The three contracts awarded between June 17, 2026, and June 17, 2026, total $539.3 million in obligations, with only one-third defense-related, signaling a civilian-heavy procurement week. The dominant theme is infrastructure and facility management, led by a $309.6 million Maritime Administration shipbuilding award to TOTE Services (85% already funded) and a $103.3 million National Park Service wastewater plant replacement to Kiewit Infrastructure West. The highest-conviction signal is the TOTE contract, offering multi-year revenue visibility but carrying fixed-price execution risk through 2029. A key risk is Kiewit's high pricing risk on a complex fixed-price construction project, which could compress margins if cost overruns emerge.

3 total filings
· daily

Significant Contract Modifications ($10M+) — June 17, 2026

The $539.3 million in significant contract modifications from June 17, 2026, is heavily weighted toward a single civilian award: TOTE SERVICES, LLC's $309.6 million firm-fixed-price delivery order from the Maritime Administration for the NSMV V vessel, which is 85% funded and provides multi-year revenue visibility through 2029. Only one of the three contracts is defense-related (Leidos Biomedical Research's $126.4 million NIH NCI GOCO facility management award), underscoring a civilian infrastructure and life sciences R&D theme rather than a defense spending surge. The highest-conviction signal is the TOTE award, which is bullish due to its high funding outlay and stable shipbuilding demand, but carries medium execution risk from the fixed-price structure. Key risks include Kiewit Infrastructure West's $103.3 million Yosemite wastewater plant contract, which is fully obligated but high-risk due to fixed-price construction exposure, and the lack of any defense-related growth catalyst in this batch.

3 total filings
· daily

Contract Deobligations Alert — June 17, 2026

The June 17, 2026 contract deobligations digest totals $539.3 million, with 1 of 3 contracts defense-related (TOTE Services' $309.6M vessel award), reflecting a civilian-heavy mix. The highest-conviction signal is TOTE Services' fully funded firm-fixed-price delivery order for the NSMV V vessel, which provides 85% funded revenue visibility through 2029 but carries fixed-price execution risk. A key watch item is Kiewit Infrastructure West Co.'s $103.3M National Park Service wastewater treatment plant contract, which is fully obligated at award but carries high execution risk due to its fixed-price nature and long duration. The digest reveals a pattern of large, non-small businesses winning competitively awarded contracts across civilian agencies (Transportation, HHS, Interior), with no sole-source or set-aside signals, indicating a neutral-to-bullish environment for established contractors in shipbuilding, life sciences R&D, and civil infrastructure.

3 total filings
· daily

Contract Option Exercises — June 17, 2026

The June 17, 2026 contract option exercise stream totals $539.3 million in obligations, with only one-third defense-related, reflecting a civilian-heavy mix led by the Department of Transportation's Maritime Administration. The highest-conviction signal is TOTE Services' $309.6 million firm-fixed-price award for NSMV V vessel construction, which is 85% funded and provides multi-year revenue visibility but carries fixed-price execution risk through 2029. Leidos Biomedical Research's $126.4 million NIH NCI facility management contract offers stable, low-risk cost-plus revenue but has limited upside as it expires in August 2024. Kiewit Infrastructure's $103.3 million Yosemite wastewater plant contract is fully obligated but carries high execution risk due to its fixed-price structure and long duration. Key watch items include TOTE's ability to deliver on budget and potential follow-on NSMV contracts from the Maritime Administration.

3 total filings
· daily

All HHS Contracts — June 17, 2026

The sole HHS contract analyzed, a $126.4M cost-plus-fixed-fee delivery order awarded to Leidos Holdings, Inc. by the NIH National Cancer Institute, represents a stable, low-risk civilian revenue stream for the company through August 2024. The contract, won under full-and-open competition, reinforces Leidos' entrenched position in federal life sciences R&D facility management, but its fixed end date and lack of options limit upside. With $74.2M already outlayed, approximately $52.2M remains in obligated funding, providing near-term visibility. The key risk is the absence of a follow-on award or extension, which could create a revenue gap for Leidos' biomedical research segment. No defense-related contracts were identified in this period, underscoring a purely civilian healthcare R&D theme.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — June 17, 2026

The three contracts totaling $539.3 million are overwhelmingly civilian, with only one-third defense-related (the TOTE Services shipbuilding award) and the remainder split between Leidos' NIH facility management and Kiewit's National Park Service infrastructure work. The strongest investment signal is the $309.6 million TOTE Services vessel contract, which is 85% funded already and provides multi-year revenue visibility, though the firm-fixed-price structure introduces execution risk over a multi-year build. The Leidos contract is a low-risk, cost-plus R&D support award, but the 2019 award date and partial funding limit forward visibility. The Kiewit wastewater plant contract carries high fixed-price execution risk on a complex build. Key watch items include TOTE's cost performance on the NSMV V vessel and potential for follow-on Maritime Administration contracts.

3 total filings
· daily

High-Value Federal Grants ($5M+) — June 17, 2026

Over the period, $539.3 million in high-value federal grants was obligated across three distinct contracts, with only one-third defense-related, skewing the aggregate toward civilian infrastructure and life sciences. The dominant theme is stable, multi-year revenue visibility for large contractors: TOTE Services’ $309.6M shipbuilding award is the highest-conviction signal, with 85% already funded, though fixed-price execution risk persists through 2029. Leidos’ $126.4M NIH facility management contract and Kiewit’s $103.3M National Park Service project offer lower-margin, low-risk cash flows. Key risks include Kiewit’s high fixed-price construction exposure and Leidos’ contract expiration in August 2024 with no options. The digest suggests a moderate, civilian-led procurement environment with limited defense catalysts.

3 total filings
· daily

General Federal Contracts — June 17, 2026

Over a single day on June 17, 2026, three federal contracts totaling $539.3 million were awarded, with only one (the $309.6M TOTE Services vessel) being defense-related, signaling a civilian-heavy procurement day. The dominant theme is large-scale, firm-fixed-price infrastructure and construction awards to non-small businesses (TOTE, Leidos, Kiewit), which carry significant execution risk due to fixed-price transfer of cost overruns to contractors. The highest-conviction signal is the TOTE Services award, which is 85% funded ($264.2M already outlaid), reducing future payment risk but exposing TOTE to potential cost overruns on a single-vessel delivery through 2029. A key risk is the concentration of all three awards to large, non-small businesses via full-and-open competition, suggesting compressed margins and no set-aside policy tailwinds.

3 total filings
· daily

S&P 500 Technology Sector SEC Filings — June 17, 2026

The 32 filings from S&P 500 Technology companies reveal a significant wave of insider selling, particularly among semiconductor and software firms, with notable transactions from CEOs at Applied Materials, CrowdStrike, and Snowflake. Despite positive insider buying from Autodesk's CEO, the overall sentiment is bearish, with 15 negative signals versus 1 positive. Period-over-period data is limited, but the lack of forward-looking guidance or capital allocation changes suggests a focus on insider activity. Key themes include concentrated selling in semiconductors (Applied Materials), consistent insider sales at Snowflake and CrowdStrike, and routine director awards at Datadog. Investors should monitor these insider patterns as potential signals of management sentiment, while the absence of material operational or financial updates keeps the focus on equity transactions.

30 high priority 2 medium 32 total filings
· daily

Nasdaq 100 Stocks SEC Filings — June 17, 2026

The 28 filings from NASDAQ-100 constituents reveal a concentrated insider selling pattern across semiconductor and tech hardware companies, with Applied Materials executives and directors selling over $26M in stock at elevated prices, while Meta directors received routine RSU grants. Tesla's CEO Elon Musk exercised a massive option award worth $7.09B, with shares withheld for taxes, maintaining a 19.9% beneficial ownership stake. No period-over-period comparisons or forward-looking guidance were present in these filings, limiting trend analysis. The dominant theme is insider selling at or near recent highs, particularly in the semiconductor equipment sector, which may signal management caution. Capital allocation actions were absent, with no dividends, buybacks, or M&A disclosed. The digest focuses on actionable signals from insider transactions and ownership changes.

23 high priority 5 medium 28 total filings
· daily

US Activist Hedge Fund Institutional SEC 13D 13G — June 17, 2026

This intelligence stream reveals significant activist and institutional activity centered on shareholder value maximization and corporate control. Key themes include explicit activist positioning by the Smith family at Sonic Automotive, who are openly seeking to take the company private, and Oramed Pharmaceuticals' vocal opposition to Nano Dimension's proposed transaction with Infinite Epigenetics. Major institutional staking is evident, with Vanguard increasing its Cogent Communications stake to 10.3% and Millennium Management taking 5%+ positions in WW International and TPG Inc. Notable exits include Lynrock Lake's aggressive sell-down of Teradata stock and Horizon Space Acquisition's de-SPAC exit. Related party block trades and insider monetization are observed at EchoStar (Charles Ergen's 53.2% static control) and Stablecoin Development Corp (formerly NovaBay), where major holders exercised warrants to maintain dominant >45% stakes. A significant M&A catalyst is pending with Holcim's public tender offer for Cementos Pacasmayo, while the Open Lending Corp acquisition at $3.15/share provides a clear arbitrage opportunity. The overall theme is one of capital reallocation, with passive institutional accumulation in select names offset by activist pressure and ownership consolidation in others, particularly in the technology and automotive sectors.

15 high priority 15 medium 30 total filings
· daily

S&P 500 Financials Sector SEC Filings — June 17, 2026

The S&P 500 Financials sector is showing a bifurcated picture: strong operational performance in insurance (Progressive) and exchange operators (CME Group) contrasts with mixed signals from major banks and card networks. Progressive's May results are a standout, with net income surging 36% YoY and a combined ratio improvement of 4.8 points to 82.1, signaling exceptional underwriting discipline. However, insider activity raises caution: the CEO of Bank of America disposed of $1M in stock, and a top executive at American Express sold $2.39M, while a 10% owner of Aflac continued a selling program. The most critical development is CME Group's planned CEO succession, which is orderly but marks a leadership change after 25 years of extraordinary growth (market cap up 8,000%). Capital markets activity is evident with American Express issuing €750M in senior notes, indicating opportunistic debt financing. The key portfolio-level theme is that property & casualty insurers are outperforming, while commercial lines and property lines at Progressive show flat or declining growth, signaling a potential shift in the insurance cycle.

7 high priority 1 medium 8 total filings
· daily

S&P 500 Consumer Staples Sector SEC Filings — June 17, 2026

The latest batch of SEC filings from the S&P 500 Consumer Staples sector reveals a period of notable insider activity, with several high-level executives and a major 10% owner executing significant stock sales, signaling potential caution at the top. While director-level awards at Hershey are routine, the sale of nearly $1.3 million in shares by the Hershey Trust and a $997,000 sale by Church & Dwight's EVP of Technology stand out as bearish signals. Leadership transitions at Clorox and Campbell's introduce execution risk, though they may also pave the way for strategic renewal. The absence of period-over-period financial comparisons, forward guidance, or capital allocation changes in these filings limits the ability to identify broad sector trends, but the insider activity pattern suggests a divergence in management conviction across the group.

10 high priority 10 total filings
· daily

S&P 500 Industrials Sector SEC Filings — June 17, 2026

From the single enriched filing for an S&P 500 Industrials constituent, CSX Corp, the intelligence stream yields a neutral, low-materiality signal centered on director compensation. The filing reveals a routine equity award to Director J. Steven Whisler, with no concurrent period-over-period comparisons, forward-looking guidance, capital allocation changes, or earnings-related data available. This event carries negligible market impact but does highlight a stable insider holdings pattern, with the director maintaining a significant position post-transaction. Overall, the industrial sector's major themes (capital spending, infrastructure, transport demand) are not addressed by this filing, and no broader portfolio-level patterns can be inferred. The key takeaway is a passive signal of no material changes or red flags at CSX Corp for the covered period.

1 high priority 1 total filings